Massachusetts Lawyers Weekly reported on a recent decision by the 1st U.S. Circuit Court of Appeals in Karth v. Keryx Biopharmaceuticals Inc., which said a Keryx Biopharmaceuticals Inc. investor cannot revive his lawsuit alleging the Boston-based pharmaceutical company hid supply chain issues. Mintz Member Laurence A. Schoen, who represented the biopharma company, discussed how the decision closes the door on ‘fraud by hindsight’ claims.

Source

Massachusetts Lawyers Weekly